Cas:33621-24-8 {[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid manufacturer & supplier

Chemical Name:{[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid

CAS.NO:33621-24-8

Synonyms:{[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid

Molecular Formula:C₈H₆N₂O₄S

Molecular Weight:226.20900

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:442.6ºC at 760mmHg

Density:1.59g/cm3

Index of Refraction:1.637

PSA:114.66000

Exact Mass:226.00500

LogP:1.50630

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like {[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,{[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,{[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid Use and application,{[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetic acid technical grade,usp/ep/jp grade.

Related News: McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. Methyl 4-bromo-5-cyano-3-methylthiophene-2-carboxylate manufacturers McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. 3-Methyl-2-phenylpyridine suppliers Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. 5-(3-amino-2,4,6-triiodo-N-methylanilino)-5-oxopentanoic acid vendor & factory The government has approved a total of 33 applications with a committed investment of Rs 5,082.65 crore under the production linked incentive scheme for active pharmaceutical ingredients, an official release said on Thursday.,McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019.